When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TKPHF - Sorrento Therapeutics: With Many Stock Catalysts It Is Not Risk-Free
Takeda Pharmaceutical Co Ltd
Sorrento Therapeutics (SRNE) was expected to commercialize ZTlido in Q4 2018. In 2019, it should help increase the revenue line and the stock price. In addition, the company should be conducting a Phase 2 trial of anti-CEA CAR-T cell therapy in 2019. On top of it, the most recent merger signed with Semnur Pharmaceuticals seems to offer new synergies and a new product candidate at Phase 3 of development. With all these good reasons to appreciate the stock, there are some risks. The company's contractual obligations show a large amount of debt that